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Abstract
Asthma is clearly related to airway or blood eosinophilia, and asthmatics with significant eosinophilia are at higher risk
for more severe disease. Eosinophils actively contribute to innate and adaptive immune responses and inflammatory
cascades through the production and release of diverse chemokines, cytokines, lipid mediators and other growth factors.
Eosinophils may persist in the blood and airways despite guidelines-based treatment. This review details eosinophil
effector mechanisms, surface markers, and clinical outcomes associated with eosinophilia and asthma severity. There is
interest in the potential of eosinophils or their products to predict treatment response with biotherapeutics and their
usefulness as biomarkers. This is important as monoclonal antibodies are targeting cytokines and eosinophils in different
lung environments for treating severe asthma. Identifying disease state-specific eosinophil biomarkers would help to
refine these strategies and choose likely responders to biotherapeutics.
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Background
Eosinophils are terminally differentiated granulocytes
that play a role in innate host defense against pathogens,
particularly parasites and viruses. Eosinophils damage
both pathogenic and host cells through the release of
toxic granule proteins and reactive oxygen species. Far
from maintaining a bystander role, however, eosinophils
actively contribute to innate and adaptive inflammatory
cascades through the production and release of diverse
chemokines, cytokines, lipid mediators and other growth
factors. Through these effector mechanisms, eosinophils
can influence tissue specific function. Asthma, a chronic
airways disease, is often related to airway or blood
eosinophilia. Importantly, asthmatics with significant
eosinophilia are at higher risk for more severe disease.
Strategies for identifying and treating these individuals
will provide much needed progress toward personalized
medical care. This review details eosinophil effector
mechanisms, surface markers, and clinical outcomes
associated with eosinophilia and asthma severity.
Key points
 Eosinophils contain highly charged proteins in their
granules, mediating toxicity toward pathogens and
tissues, and produce a variety of inflammatory
proteins which further contribute to tissue
pathology
 Eosinophil accumulation in the airways in severe
asthma correlate with markers of local tissue and
extracellular matrix (ECM) remodeling
 Eosinophilia is a marker of severe asthma and those
at risk for more frequent exacerbations
Unmet needs
 Understanding phenotypic and functional plasticity
of eosinophils in the context of the changing or
altered lung microenvironment occurring within
different asthma endotypes and severity
 Discovery of how the phenotype and function of
eosinophils contribute to asthma exacerbations
 Identification of novel eosinophil-restricted biomarkers,
both internal and external, with potential to be targeted
for therapeutic intervention with specific biotherapeu-
tics and monoclonal antibodies.
Effector and pro-inflammatory mechanisms of
eosinophils
Eosinophils are terminally differentiated granulocytic
effector cells that produce and store biologically active
molecules, including the cytotoxic proteins major basic
protein (MBP), eosinophil peroxidase (EPX), eosinophil
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cationic protein (ECP), and eosinophil derived neurotoxin
(EDN), lipid mediators, chemotactic peptides, as well as
cytokines (Fig. 1) [1, 2]. They are believed to play an im-
portant role in the innate immune system by contributing
to host resistance to parasites, particularly helminths, but
also antimicrobial activities toward bacterial, viral and
fungal pathogens [3]. These pathogens can be killed by
granule proteins released from activated eosinophils [4].
However, the eosinophil-derived granule proteins are not
only toxic to pathogens but also to other cells within im-
mune responses, causing tissue damage and consequently
organ dysfunction (Fig. 2). MBP is expressed as two
homologs, MBP-1 and MBP-2; MBP-1 has a markedly
basic pH and is directly toxic to host and parasite cells [5].
EDN exerts antiviral effects through RNase activity [6].
Besides granule proteins, eosinophil reactive oxygen
species have also been shown to damage cells and tissues.
EPX catalyzes the development of reactive oxygen species
in the presence of hydrogen peroxide. Not only the cyto-
toxic activity itself, but also the interactions with other im-
mune cells, enhanced the notion of a pro-inflammatory
role for the eosinophil [7]. It could be demonstrated that
MBP induces histamine release by both mast cells and ba-
sophils [8]. Furthermore, EPX in combination with H2O2
and halides was shown to induce mast cell secretion [9].
To release granule proteins and to produce toxic
oxygen radicals, eosinophils need to be activated (Fig. 2).
Following priming with eosinophil hematopoietins, such
as IL-5 and GM-CSF, eosinophils exhibit an increased
capacity to respond to other inflammatory mediators
[10]. Adhesion molecule engagement can also stimulate
eosinophil activation [11]. Activation of the mitogen-
activated protein kinase (MAPK) pathway is central for
degranulation [12]. Granule proteins can be detected in
tissues following eosinophil degranulation, sometimes
even in the absence of sustained eosinophil infiltration
[13], suggesting not only little degradation but also lim-
ited toxicity under such conditions. Extracellular granule
proteins can be detected in association with collagen
fibers, within DNA traps and extracellular free granules
(Fig. 2) [14]. MBP has been shown to occur as an amyl-
oid structure within flame figures of patients with
eosinophilic dermatitis [15] and eosinophil DNA traps
have been demonstrated in multiple eosinophilic
diseases, including eosinophilic asthma [16]. Although
the DNA scaffold clearly increases the toxicity of granule
proteins against bacteria, it remains unclear whether eo-
sinophil DNA traps mediate or limit immunopathology
[17]. Extracellular free granules are believed to be the
result of eosinophil cytolysis, a non-apoptotic cell death
Fig. 1 Surface molecules expressed by human eosinophils. There is some overlap among categories for some of these proteins. Common names for
chemokine (CC and CXC) receptors, toll-like receptors (TLRs), and others were sometimes used instead of the CD names because of the greater use and
familiarity among most readers of the former. The asterisk indicates activated eosinophils. C3aR, C3a receptor; CysLT, cysteinyl leukotriene receptor type;
EMR1, epidermal growth factor–like module containing mucin-like hormone receptor-like 1; fMLPR, formyl-methionyl-leucyl-phenylalanine
receptor; GM-CSF, granulocyte-macrophage colonystimulating factor; IFN, interferon; IL, interleukin; LIR, leukocyte immunoglobulin-like
receptor; LTB4R, leukotriene B4 receptor; P2X and P2Y, two types of purinergic receptors; PAFR, platelet activating factor receptor; PIR,
paired immunoglobulin-like receptor; TNF, tumor necrosis factor. (Courtesy of Jacqueline Schaffer, MAMS, Chicago, IL.). Reproduced with
permission [27]
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occurring as a consequence of utmost eosinophil activa-
tion [18] (Fig. 2). The molecular mechanism leading to
eosinophil cytolysis, however, is not known.
The eosinophil’s granule proteins exhibit different tox-
icity when tested in vitro. While EDN is only marginally
toxic, MBP, EPO and ECP are toxic to a variety of
tissues, including heart, brain, skin, and bronchial epi-
thelium [4]. ECP has been shown to be 8–10 times more
potent than MBP [19]. Recently, however, it has been
demonstrated that the toxicity of MBP is regulated by
aggregation [15]. Following degranulation, MBP forms
functional amyloid structures exhibiting high toxicity.
The continuation of the aggregation process, however, is
associated with a loss of toxicity explaining the little
damage seen in tissues containing large MBP deposits.
MBP can stimulate histamine and leukotriene C4 release
from human basophils and can activate mast cells.
Interestingly, heparin, a product of mast cells, can rap-
idly inhibit MBP toxicity [15]. Therefore, MBP toxicity is
not stable and depends on polymorphic self-association
pathways. Taken together, first insights have been
obtained on how the non-selective mechanism of MBP
toxicity toward host cells, such as bronchial epithelial
cells in asthma, is regulated.
In addition to the direct tissue toxic effect of eosino-
phil activation and degranulation, eosinophils can
contribute to inflammatory pathways through their cap-
acity to synthesize and secrete a remarkable number of
pro-inflammatory cytokines and chemokines [20] (Fig. 1).
For example, eosinophils may produce type-2 pathway
factors such as interleukin (IL)-4, IL-5, IL-13, and IL-25,
and may have been shown to do so in the airways of
asthmatics [21]. Chemokines such as CCL5/RANTES,
CCL11/eotaxin and CCL3 are secreted by eosinophils
and can recruit leukocytes to the site of eosinophilic
inflammation. Alternately, following allergen challenge, air-
way eosinophils have been shown to express GM-CSF and
CXCL8/IL-8 [22] thereby inducing neutrophil recruitment.
Eosinophils may contribute to airway remodeling in severe
asthma through release of transforming growth factor β-1
[23, 24]. Interferon-gamma, a type-1 cytokine secreted by
eosinophils, can also potently activate eosinophils [25], and
is elevated in the serum of some acute severe asthmatic pa-
tients [26], underscoring the importance of these pathways
in severe asthma.
The pleiotropic effects of eosinophils therefore in-
clude host defense, host tissue damage, regulation and
potentiation of inflammatory cascades, each of which
may contribute to asthma severity. Therapies that
target eosinophils may therefore help control diseases
associated with eosinophil-mediated tissue damage and
inflammation [7, 27].
Degranulation
Granule protein release
Cell free granules
Granule protein release
Killing of pathogens & tissue damage
Cytolysis
DAMPs
Activation
DNA
Extracellular 
DNA traps
Fig. 2 Eosinophil effector mechanisms following eosinophil activation. Among other pro-inflammatory mediators, eosinophils release granular
proteins and mitochondrial DNA. As a consequence, eosinophil granule proteins mediate toxicity toward pathogens or host cells, either alone
and with extracellular DNA traps. Cytolysis is associated with massive granule protein secretion. Moreover, cytolysis most likely results in the release of
damage-associated molecular pattern molecules (DAMPs), which are known to trigger inflammatory responses. The release of DAMPs from cytolytic
eosinophils, however, remains to be demonstrated; hence, this pathway is indicated with dashed arrows
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Markers on eosinophils
Like all leukocytes, the eosinophil displays a wide range of
cell surface proteins, glycans, and lipids (see Fig. 1) [2, 28].
Functions associated with this phenotype include adhesion,
migration, proliferation, activation and promotion of sur-
vival and death. Some cell surface receptors are G-protein
coupled receptors (e.g., chemokine receptors), some are
members of the immunoglobulin gene superfamily or have
enzymatic activity, while others allow the eosinophil to
interact with various soluble mediators released by other
immune-related proteins such as cytokines and immuno-
globulins. Eosinophils are also equipped with certain intra-
cellular receptors that regulate function (e.g., some toll-like
receptors and the glucocorticoid receptor). The only
known surface structure that is completely unique to the
eosinophil is epidermal growth factor–like module
containing mucin-like hormone-like receptor 1 (EMR1)
[29, 30]. Other cell surface structures are relatively specific
for eosinophils, but are also expressed on mast cells and
basophils, such as CCR3 (the receptor for eotaxins),
CRTh2 (the receptor for prostaglandin D2), the IL-5
receptor, and Siglec-8. Glycomic analysis of materials
derived from cell lysates showed sizable amounts of
terminal N-acetylglucosamine containing structures in
both eosinophils and basophils, while mast cells have more
in the way of sialylated terminal glycans [31].
Markers of eosinophil activation may differ among the
atopic diseases, both by site and severity. Identification
of markers on tissue resident eosinophils has been
limited by the availability of adequate tissue for this
analysis, particularly in severe asthma. An extensive
review on the role of allergic biomarkers of asthma and
other atopic disease was published recently by the
World Allergy Organization [32].
Airway eosinophilia occurs in approximately 50 % of
severe asthma patients, and is especially prominent in
severe asthmatics with Type 2-like late onset disease [33].
The number of eosinophils in sputum can be used as a
marker of disease severity, with strong associations
between airway eosinophilia and severity of disease symp-
toms, worsened lung function, and incidence of fatal
asthma [33, 34]. Eosinophil numbers in the airways correl-
ate with tissue biomarkers such as periostin, fractional
exhaled nitric oxide expression of chemokine CCL26
(eotaxin-3), and thickening of the reticular basement
membrane with deposition of extracellular matrix (ECM)
proteins, specifically laminin and tenascin [35–37]. Airway
eosinophils in asthma exhibit a hyperadhesive phenotype
towards various ECM components, and are thought to
play an active role in lung tissue remodeling processes and
thickening of the reticular basement membrane through
their release of TGF-β and proteases [38, 39].
Following recruitment into the airways, there are
certain predictable and characteristic changes in the
surface phenotype of the eosinophil reflecting their
transendothelial and transepithelial migration and
interactions with the tissue and ECM, such as shedding
of L-selectin (CD62L), CD31, the IL-5 receptor and
CD162, upregulation and/or enhanced function of
CD11b, CD11c, CD11d, CD35, CD44 (the receptor for
hyalouronic acid), CD66 and CD81, and the de novo
appearance of HLA-DR, ICAM-1 and CD69 [40, 41].
Upregulation of an allosterically active form of integrin
CD11b is particularly characteristic of the airway eo-
sinophil phenotype in asthma, mediating enhanced
adhesion and migration of eosinophils to fibrinogen
and diverse ECM ligands [42]. CD11b was also
recently established as a primary adhesive and pro-
migratory receptor for periostin [43]. An interesting
possibility has been proposed that in patients with
severe eosinophilic asthma, in situ maturation of
CD34+ and CD125+ (IL-5Rα) eosinophil progenitors
rather than recruitment of mature cells could also
contribute to persistent airway eosinophilia [44, 45],
potentially governed by IL-5 produced by group 2
innate lymphoid cells [46].
By now, it is widely recognized that asthma is a highly
heterogeneous disease. Several endotypes potentially
exist even in forms of disease characterized by eosino-
phil presence in the airways, where diverse factors could
dictate specific eosinophil phenotypes [47]. Our under-
standing of eosinophil phenotypic plasticity across differ-
ent asthma endotypes is currently lacking. Identifying
disease state-specific eosinophil biomarkers would not
only allow for better understanding of the nature of
eosinophil-tissue relationship, but also would help to
refine our strategies for targeting these cells in different
lung microenvironments.
Eosinophils, severe asthma and allergic
inflammation
Eosinophils are present in the blood and some tissues of
healthy individuals and are increased in numbers in a
variety of disease states. Systemic diseases, such as para-
sitic infection, drug allergy, vasculitis, or malignancy,
can present with blood or organ-specific eosinophilia.
Similarly, eosinophilia can be a marker of many diseases
of the airway, such as chronic sinusitis, chronic obstruct-
ive pulmonary disease, hypersensitivity pneumonitis,
acute and chronic eosinophilic pneumonia, and of
course, asthma. Indeed, elevated eosinophil levels are
seen in approximately half of individuals with asthma
[48–51]. Here we discuss the relationship between atopy
and eosinophilia as it may pertain to severe asthma.
Atopy is a prominent feature of some asthma pheno-
types. Environmental allergens, such as Dermatophagoides
spp., Alternaria alternata, pollens and pet dander have
been implicated in the development, or severity, of asthma
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in epidemiologic studies [52, 53]. These allergens presum-
ably exert their effects through activation of mast cells
and basophils. Mast cells are bone marrow derived cells of
the innate immune system which are induced by stem cell
factor and IL-3, mature and reside in tissues, and can
proliferate in tissues after maturation. Mast cell granules
contain pre-formed mediators including histamine, tryp-
tase, and variably other enzymes such as chymase and
carboxypeptidase. Allergen-specific IgE antibodies nonco-
valently bind to the high affinity IgE receptor (FcεRI) on
the surface of tissue resident mast cells. Mast cells can be
activated by cross-linking of those FcεRI molecules upon
exposure of the mast cell to the offending antigen. This
event initiates signalling cascades within the mast cell
involving protein tyrosine kinases. Three main pathways
predominate. The first involves phosphatidylinostol
bisphosphate catabolism and activation of protein kinase
C, which together facilitate mast cell degranulation and
release of the aforementioned preformed mediators. The
mast cell activation cascade also activates phospolipase
A2, which induces development of arachadonic acid,
and the subsequent production of the lipid mediators
prostaglandin D2 and the cysteinyl-leukotrienes. Finally,
activation of the kinase cascades leads to nuclear
translocation of transcription factors which stimulate gene
expression and protein production of cytokines such as
IL-4, IL-5, IL-13 and tumor necrosis factor. The IL-5
released stimulates bone marrow production and release
of eosinophils, which are then recruited to tissues via
ICAM-1, P-selectin and VCAM-1. Type-2 helper CD4+ T
lymphocytes are recruited, and chronically contribute
proinflammatory mediators which potentiate this cycle.
As discussed earlier in this chapter, eosinophils can
cause direct toxic effects on host tissues and promote
inflammatory cascades through release of a variety of
inflammatory mediators. These effects are reflected in
clinical outcomes, particularly severity of asthma and
risk of exacerbation. Severe asthma is defined as asthma
that requires treatment with high dose inhaled cortico-
steroids (ICS) plus a second controller for the previous
year, and/or systemic corticosteroids for at least half of the
previous year, to prevent it from becoming ‘uncontrolled’
or which remains ‘uncontrolled’ despite this therapy.
Uncontrolled asthma is defined as the presence at least
one of the following characteristics: persistently poor
symptom control, two or more exacerbations requiring
bursts of systemic corticosteroids in the preceding
year, at least one serious exacerbation requiring
hospitalization in the previous year, or chronic airflow
limitation of FEV1 < 80 % predicted with FEV1/FVC
ratio less than the lower limit of normal [54].
An analysis using the National Health and Nutrition
Examination Survey, an annual cross-sectional survey of
the US general population, revealed that individuals with
asthma and blood eosinophil count greater than 300
cells per microliter were more likely to report asthma at-
tacks [55]. Similarly, adults with higher blood eosinophil
counts seem to have more frequent exacerbations than
those with low eosinophil counts [56]. In the National
Institutes of Health-sponsored Severe Asthma Research
Program (SARP), which enrolled and carefully assessed
large cohorts of mild, moderate, and severe asthmatic
adults and children, eosinophilic and other cellular markers
were assessed in relationship to disease outcomes. Those
individuals with significant sputum eosinophilia, often in
the presence of sputum neutrophilia, had more severe
asthma. Importantly, these groups also had increased
medication use, bursts of systemic corticosteroids, and
hospitalizations [57, 58]. Reduction of eosinophil levels in
blood and sputum is also related to fewer exacerbations
and less health care utilization for asthma [59, 60]. How-
ever, in some severe asthmatics, high eosinophil levels can
persist despite the use of high dose controller medications,
including corticosteroids [61].
Importantly, eosinophilia is a marker of beneficial
response to corticosteroid therapy [61–64]. Therefore,
identification of asthmatics with significant eosinophilic
inflammation is an important step towards practicing
personalized, or precision, medicine. Eosinophilia can be
present in the airway lumen, bronchial walls, and blood,
however levels in these compartments do not always
correlate. Cell counts and gene expression patterns in
the sputum can accurately identify steroid-responders
[62, 64]; however, induced sputum collection and
measurement is time consuming, labor-intensive, and
not available for routine use [65]. Blood eosinophil
measurements, while simple and widely available, are a
good predictor of steroid response [59, 66]. However,
blood eosinophil levels can fluctuate throughout the day,
with higher levels in the evening, impacting accuracy of
measurements. ECP can be used as a biomarker of
eosinophilic inflammation, and can be measured in both
blood and airway compartments. In plasma, ECP may be
a time sensitive marker of eosinophil activation [67].
Anti-IL-5 monoclonal antibodies, mepolizumab, and
reslizumab are available for the treatment of severe
eosinophilic asthma. Phase three studies supported its
use for reduction of exacerbation frequency and steroid
sparing effect [68–70]. Long term effects on airway
remodeling remain to be seen.
Conclusions
Eosinophils can affect airway biology as both a source of
epithelial damage and airway remodeling in asthma. As
such eosinophils contribute to the severity of asthma
and may persist despite guidelines-based treatment.
Eosinophils also may act as biomarkers for severity of
asthma and may also identify the response to treatment
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and control for severe asthma. Eosinophils or their
products are of great interest for potential usefulness in
predicting treatment response and as biomarkers.
This is especially important since new and expensive
biotherapeutic treatments (monoclonal antibodies) are
being directed towards eosinophils in the treatment
of severe asthma.
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